Precision-engineered cancer immunotherapies like CAR T-cell approaches aim to empower the patient’s own immune system to target and eliminate cancer. Targeted immunotherapies are urgently needed for solid tumors, which are notoriously difficult to treat with many existing approaches.

In this application note, you will explore:

  • How CytoTronics’ electrical imaging platform enables non-destructive monitoring of immune-mediated cytotoxicity in HeLa-CD19 cells over time
  • Quantitative, time-resolved data capturing CAR T-cell activity across a range of effector-to-target (E:T) ratios
  • Comparison of cell-killing activity between CD-19 CAR T-cells and mock CAR T-cells

Measuring the effects of targeted vs untargeted CAR T-cell treatment on cancer cells at different E:T ratios.